Medigene is responsible for the clinical development of Veregen®, for which it obtained approval, and which is used in the treatment of genital warts. The ointment is marketed globally by business partners.
Medigene has successfully completed two Phase II clinical trials for EndoTAG®-1, a drug candidate for the treatment of pancreatic cancer and triple-negative breast cancer.
Medigene is currently conducting research into the application of AAVLP technology for the treatment of cancer and viral infections, and is examining the possibility of using AAV libraries to systematically identify suitable vaccine candidates.
„Our company’s financial results and operational development in the first months 2013 are in line with our expectations and demonstrate a positive trend.“Peter Llewellyn-Davies, CFO